BioLineRX Ltd (BLRX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 23, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BLRX SEC filings page.
BioLineRX Ltd (BLRX) reported $1.2M in revenue for fiscal year 2025, down 95.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest figures describe a small-revenue operation where losses narrowed, while cash needs remain tied to financing and investing flows.
Revenue fell from$28.9M in FY2024 to$1.2M in FY2025, yet the net loss narrowed. That makes the earnings improvement non-sales-led; operating cash outflow also fell across those years, while financing was positive and investing was negative in FY2025.
The near-match between FY2025 free cash flow of
FY2025 total assets of
Financial Health Signals
BioLineRX Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BioLineRX Ltd passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
BioLineRX Ltd reported a net loss of $2.0M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
BioLineRX Ltd held $3.3M in cash against $977K in long-term debt as of Q4 2025, with $12.1M of liabilities due within a year.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
BLRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'246-K | Q4'2310-K | Q2'2310-Q | Q4'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $304K-94.4% | N/A | $5.4M | N/A | $0 | N/A | N/A |
| Interest Expense | N/A | $276K-86.8% | N/A | $2.1M+55.9% | N/A | $1.3M+252.8% | N/A | $379K+56.6% |
| Net Income | N/A | -$3.9M-914.0% | N/A | $484K+102.6% | N/A | -$18.5M-149.2% | N/A | -$7.4M-8.8% |
| Diluted Shares (Avg) | N/A | N/A | N/A | 1.20B+29.8% | N/A | 923M | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Income Tax, EPS (Basic), EPS (Diluted).
BLRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'246-K | Q4'2310-K | Q2'2310-Q | Q4'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $40.9M+5.1% | $43.3M-33.0% | $38.9M-39.1% | $64.6M+9.6% | $63.9M-16.3% | $58.9M-13.1% | $76.4M-6.2% | $67.8M-25.7% |
| Current Assets | $23.7M-12.6% | $31.9M-35.1% | $27.1M-42.6% | $49.1M+41.6% | $47.2M-9.3% | $34.7M-21.3% | $52.0M-9.4% | $44.1M-34.2% |
| Cash & Equivalents | $3.3M-68.9% | $7.2M-25.3% | $10.4M+145.3% | $9.6M-4.8% | $4.3M-59.8% | $10.1M-27.8% | $10.6M-18.5% | $14.0M-19.9% |
| Inventory | $2.1M-31.7% | $2.9M-21.6% | $3.1M+61.0% | $3.6M | $2.0M | N/A | $0 | N/A |
| Total Liabilities | $17.6M-31.0% | $23.2M-54.2% | $25.4M-49.8% | $50.6M+33.6% | $50.7M+98.5% | $37.9M+236.1% | $25.5M+92.0% | $11.3M-35.4% |
| Current Liabilities | $12.1M-21.3% | $15.5M-49.3% | $15.4M-64.0% | $30.5M+145.2% | $42.8M+300.6% | $12.4M+29.2% | $10.7M+9.9% | $9.6M-2.9% |
| Non-Current Liabilities | $5.4M-45.8% | $7.7M-61.6% | $10.0M+26.8% | $20.1M-21.0% | $7.9M-46.7% | $25.4M+1452.9% | $14.9M+314.6% | $1.6M-78.2% |
| Long-Term Debt | $977K-9.6% | $998K-23.8% | $1.1M-16.2% | $1.3M-17.6% | $1.3M-25.4% | $1.6M+9.4% | $1.7M+0.2% | $1.5M-14.6% |
| Total Equity | $23.3M+73.4% | $20.1M+44.5% | $13.5M+1.8% | $13.9M-34.0% | $13.2M-74.0% | $21.1M-62.8% | $50.8M-25.3% | $56.6M-23.4% |
| Retained Earnings | -$401.0M-0.3% | -$398.6M-2.0% | -$399.8M-2.4% | -$390.8M-8.4% | -$390.6M-18.4% | -$360.7M-13.6% | -$330.0M-8.2% | -$317.4M-7.6% |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill.
BLRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
BLRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'246-K | Q4'2310-K | Q2'2310-Q | Q4'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Net Margin | N/A | -1296.0% | N/A | 9.0% | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -19.6%-23.1pp | N/A | 3.5%+91.6pp | N/A | -88.1%-74.9pp | N/A | -13.2%-3.9pp |
| Return on Assets | N/A | -9.1%-9.9pp | N/A | 0.8%+32.2pp | N/A | -31.5%-20.5pp | N/A | -11.0%-3.5pp |
| Current Ratio | 1.95+0.2x | 2.06+0.4x | 1.76+0.7x | 1.61-1.2x | 1.10-3.8x | 2.79-1.8x | 4.87-1.0x | 4.58-2.2x |
| Debt-to-Equity | 0.040.0x | 0.050.0x | 0.080.0x | 0.090.0x | 0.10+0.1x | 0.080.0x | 0.030.0x | 0.030.0x |
| Asset Turnover | N/A | 0.01-0.1x | N/A | 0.08+0.1x | N/A | 0.00 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioLineRX Ltd BLRX | FY2025 | $1.2M | -$2.0M | N/A | $10.8M | — |
| Edesa Biotech, Inc. EDSA | FY2025 | N/A | -$7.2M | N/A | $28.3M | — |
| Tharimmune, Inc. THAR | FY2025 | N/A | -$35.9M | N/A | $187.4M | — |
| MetaVia Inc. MTVA | FY2025 | N/A | -$13.0M | N/A | $9.6M | — |
| Portage Biotech Inc. PRTG | FY2018 | N/A | $123.7M | N/A | $15.5M | — |
| Lisata Therapeutics, Inc. LSTA | FY2025 | $170K | -$17.0M | N/A | $11.3M | — |
Where BioLineRX Ltd Ranks
Frequently Asked Questions
What is BioLineRX Ltd's annual revenue?
BioLineRX Ltd (BLRX) reported $1.2M in total revenue for fiscal year 2025. This represents a -95.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioLineRX Ltd's revenue growing?
BioLineRX Ltd (BLRX) revenue declined by 95.9% year-over-year, from $28.9M to $1.2M in fiscal year 2025.
Is BioLineRX Ltd profitable?
No, BioLineRX Ltd (BLRX) reported a net income of -$2.0M in fiscal year 2025.
How much debt does BioLineRX Ltd have?
As of fiscal year 2025, BioLineRX Ltd (BLRX) had $3.3M in cash and equivalents against $977K in long-term debt.
What is BioLineRX Ltd's return on equity (ROE)?
BioLineRX Ltd (BLRX) has a return on equity of -8.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BioLineRX Ltd's free cash flow?
BioLineRX Ltd (BLRX) recorded an outflow of $8.1M in free cash flow during fiscal year 2025. This represents a 81.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioLineRX Ltd's operating cash flow?
BioLineRX Ltd (BLRX) recorded an outflow of $8.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BioLineRX Ltd's total assets?
BioLineRX Ltd (BLRX) had $40.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioLineRX Ltd's capital expenditures?
BioLineRX Ltd (BLRX) invested $25K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is BioLineRX Ltd's current ratio?
BioLineRX Ltd (BLRX) had a current ratio of 1.95 as of fiscal year 2025, which is generally considered healthy.
What is BioLineRX Ltd's debt-to-equity ratio?
BioLineRX Ltd (BLRX) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioLineRX Ltd's return on assets (ROA)?
BioLineRX Ltd (BLRX) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BioLineRX Ltd's P/E ratio?
BioLineRX Ltd (BLRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $10.8M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioLineRX Ltd's price-to-sales ratio?
BioLineRX Ltd (BLRX) trades at 9.2x sales, its market capitalization divided by revenue of $1.2M revenue, FY2025. The market capitalization is $10.8M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BioLineRX Ltd's Piotroski F-Score?
BioLineRX Ltd (BLRX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioLineRX Ltd's earnings high quality?
BioLineRX Ltd (BLRX) reported a net loss of $2.0M while operations used $8.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.